Public Policy
Clinical Pharmacology & Therapeutics (2007) 81, 129–133. doi:10.1038/sj.clpt.6100014
Drug Development and the FDA's Critical Path Initiative
1The Critical Path Institute, Tucson, Arizona and Rockville, Maryland, USA
Correspondence: Dr RL Woosley, (Rwoosley@C-Path.org)
Abstract
Advances in biomedical research over recent decades have substantially raised expectations that the pharmaceutical industry will generate increasing numbers of safe and effective therapies. However, there are warning signs of serious limitations in the industry's ability to effectively translate biomedical research into marketed new therapies. Clinical pharmacologists should be aware of these signals and their potential impact. Here, we discuss a strategy, where clinical pharmacology can play an important role to improve the process of drug development.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Biomarker Development, Commercialization, and Regulation: Individualization of Medicine Lost in TranslationClinical Pharmacology & Therapeutics News and Views
